Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3687 Lutetium-177 DOTATATE PRRT versus PRRT plus chemotherapy in metastatic well differentiated FDG-avid GEP-NETs – Results from a prospective cohort

Introduction: Combination therapy with PRRT and Capecitabine-Temozolomide (CAPE-TMZ) has benefited patients with FDG avid well-differentiated GEP-NETs.

Conference:

Presenting Author:

Authors: Puranik A, Rangarajan V, Shrikhande S, Ramaswamy A, Ostwal V,

Keywords: PRRT, capecitabine, temozolomide, FDG PET, DOTA PET,

#3417 SARS-CoV-2 vaccination site as possible pitfall on somatostatin receptor imaging

Introduction: SARS-CoV-2 (COVID19) vaccinations have shown high efficacy. Therefore, increased chances exist that patients undergoing Peptide Receptor Radionuclide Therapy (PRRT) or radionuclide imaging for Neuroendocrine Tumors (NETs) may have being recently vaccinated.

Conference:

Presenting Author: Kolade O

Authors: Kolade O, Ayeni A, Brink A, Steyn R, Prasad V,

Keywords: COVID-19, SARS-CoV-2, Lu-177 DOTATATE, Ga-68 DOTANOC, Vaccination, PRRT, Neuroendocrine Tumor,

#3292 Neuroendocrine differentiation of metastasised castrate-resistant prostate cancer patients referred for radioligand therapy with Lu-177 PSMA

Introduction: Neuroendocrine differentiation (NED) of metastasised castrate-resistant prostate cancer (mCRPC) is normally associated with poor prognosis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Grunert M, Miksch J, Steinacker J, Zengerling F, Glatting G,

Keywords: NED, mCRPC, CgA, NSE, RLT, overall survival,

#3291 Changes in Eosinophil as potential marker for immune-related changes associated with PRRT in NET

Introduction: Eosinophil (E) accumulation under immune checkpoint inhibitors (ICI) in cancer patients’ blood has been shown to have predictive value. Peptide Receptor Radionuclide Therapy (PRRT) can remodel tumor environment for ICI in G1 / G2 neuroendocrine tumor patients.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Grunert M, Quast D, Ettrich T, Glatting G, Beer A,

Keywords: eosinophil, PRRT, NET, tumor microenvironment,

#3290 Intratumoral serotonin might decrease the efficacy of PRRT in ileal neuroendocrine tumors

Introduction: Partial remission can be achieved by peptide receptor radionuclide therapy (PRRT) in only roughly 20% of patients with midgut neuroendocrine tumor (NET). This low remission rate can be due to the radioprotective role of stored intracytoplasmic serotonin in NET cells. If blocked, e.g. by telotristatethyl, PRRT efficacy might be increased.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Prasad V, Klöppel G, Lupp A, Wirtz R, Kaemmerer D,

Keywords: Ileal NET, serotonin, radioprotector, PRRT, immunohistochemistry, TPH1,